Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients is a phase 2, interventional study registered as NCT05771181 by Fudan University, with a registry enrolment figure of 25 participants, started 2023-03-01 and due to reach its primary completion in 2025-12. Interventions recorded: Vitamin E; Fruquintinib; Tislelizumab. Conditions listed: Colorectal Cancer; Microsatellite Stable Colorectal Carcinoma. Primary outcome: objective response rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.